Isavuconazole (BAL4815) is an experimental triazole antifungal. Its prodrug isavuconazonium sulfate (BAL8557) is currently in two Phase III clinical trials (SECURE and VITAL) the results of which are expected in the second half of 2013.On May 28 2013 Basilea Pharmaceutica the maker of the drug announced it had been granted orphan drug status by the U.S. Food and Drug Administration (FDA).
This page contains content from the copyrighted Wikipedia article "Isavuconazole"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
